Mechanistically, ARID1A interacts with EZH2 via its C-terminal region and antagonizes EZH2-mediated IFN responsiveness, and the DUF3518 domain of ARID1A is essential for tumor cell IFN-γ response (79). Here, ARID1A is linked to neoplasm.